$128.73
+63.33 (+96.83%)
1Y
About
Halozyme Therapeutics, Inc. is a biopharmaceutical company headquartered in San Diego, California, with operations spanning the United States, Switzerland, Ireland, Belgium, Japan, and other international markets. At its core is the proprietary ENHANZE drug delivery platform, which utilizes a patented recombinant human hyaluronidase enzyme (rHuPH20). This innovative technology significantly enhances the subcutaneous (under-the-skin) administration of a diverse range of injectable medicines. T...
HQ: San Diego, CA · Founded: 1998 · Employees: 423 · CEO: Helen I. Torley ·Revenue (TTM): $1.7B
www.halozyme.com Company Info
Sector
Health Care Industry
Biotechnology Country
United States Exchange
NASDAQ Currency
USD Financial Metrics
Day Range
$126.13 $128.94
52-Week Range
$61.23 $128.94
Prev Close
$128.01 Market Cap
$13.3B P/E Ratio
— Forward P/E
11.0 EPS (TTM)
$3.42 Profit Margin
24.9% Div Yield
— Annual Dividend
— Avg Volume
2M Beta
0.54 Track HALO in your portfolio
See how Halozyme Therapeutics, Inc. affects your portfolio risk, drawdown, and diversification.
Get started